Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.45 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31365231 | 0.91 | CYP2B6 (0.52) | CYP2B6TENT4ATENT4BCNR2 | |
| SCHEMBL22898887 | 0.91 | CYP2B6 (0.52) | CYP2B6TENT4ATENT4BCNR2 | |
| SCHEMBL22898996 | 0.91 | CYP2B6 (0.46) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898991 | 0.84 | CYP2B6 (0.42) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21358612 | 0.84 | CYP2B6 (0.44) | CYP2B6TENT4ATENT4BCNR2 | |
| SCHEMBL25832456 | 0.84 | CNR2 (0.35) | CNR2 | |
| SCHEMBL31365208 | 0.83 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B | |
| SCHEMBL27200083 | 0.83 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21359914 | 0.80 | CYP2B6 (0.42) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898928 | 0.80 | CYP2B6 (0.42) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.